Ziel
The first product that AURA will launch to the market will be OSCANN, a diagnosis platform that will allow better, faster
and more accurate diagnosis of neurological disorders affecting Europe’s population in general, but specially youngsters
(e.g. ADHD) and elders (e.g. Parkinson). OSCANN allows for the measurement and analysis of ocular and oculocephalic
movements (OM/OCM) and combines the result with data obtained from other sources (clinical histories, medical
explorations, complementary tests and biomarkers) using Artificial Intelligence (AI) techniques to improve significantly the
quality of medical diagnosis in early stages.
Wissenschaftliches Gebiet
Not validated
Not validated
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesclinical medicinepsychiatry
- natural sciencescomputer and information sciencesartificial intelligencecomputer visionmotion analysis
- medical and health sciencesbasic medicineneurologyparkinson
Programm/Programme
- H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
- H2020-EU.3.1.4. - Active ageing and self-management of health
- H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.1.6. - Health care provision and integrated care
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SMEINST-1-2016-2017
Finanzierungsplan
SME-1 - SME instrument phase 1Koordinator
28045 MADRID
Spanien
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).